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Background. The catecholamine reuptake inhibitors methylphenidate (MPH) and atomoxetine (ATX) are the most
common treatments for attention deﬁcit hyperactivity disorder (ADHD). This study compares the neurofunctional
modulation and normalization effects of acute doses of MPH and ATX within medication-naive ADHD boys during
working memory (WM).
Method. A total of 20 medication-naive ADHD boys underwent functional magnetic resonance imaging during a para-
metric WM n-back task three times, under a single clinical dose of either MPH, ATX or placebo in a randomized, double-
blind, placebo-controlled, cross-over design. To test for normalization effects, brain activations in ADHD under each
drug condition were compared with that of 20 age-matched healthy control boys.
Results. Relative to healthy boys, ADHD boys under placebo showed impaired performance only under high WM load
together with signiﬁcant underactivation in the bilateral dorsolateral prefrontal cortex (DLPFC). Both drugs normalized
the performance deﬁcits relative to controls. ATX signiﬁcantly enhanced right DLPFC activation relative to MPH within
patients, and signiﬁcantly normalized its underactivation relative to controls. MPH, by contrast, both relative to placebo
and ATX, as well as relative to controls, upregulated the left inferior frontal cortex (IFC), but only during 2-back. Both
drugs enhanced fronto-temporo-striatal activation in ADHD relative to control boys and deactivated the default-mode
network, which were negatively associated with the reduced DLPFC activation and performance deﬁcits, suggesting
compensation effects.
Conclusions. The study shows both shared and drug-speciﬁc effects. ATX upregulated and normalized right DLPFC
underactivation, while MPH upregulated left IFC activation, suggesting drug-speciﬁc laterality effects on prefrontal
regions mediating WM.
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Introduction
Attention deﬁcit hyperactivity disorder (ADHD) is
characterized by age-inappropriate symptoms of in-
attention, impulsivity and hyperactivity (APA, 2000).
One of the key neuropsychological deﬁcits is in work-
ing memory (WM) (Martinussen et al. 2005), deﬁned as
the temporary storage and manipulation of informa-
tion (Baddeley, 1996).
Children with ADHD have consistently shown
deﬁcits in verbal–auditory and visuo-spatial WM tasks
(Rommelse et al. 2008; Toplak et al. 2008; Gau & Shang,
2010; Rhodes et al. 2011; for meta-analyses, see
Martinussen et al. 2005 and Willcutt et al. 2005) includ-
ing visual–object (Pasini et al. 2007) and phonological
n-back tasks (Klein et al. 2006; Pasini et al. 2007;
Kobel et al. 2009). These deﬁcits have been shown to
be underpinned by functional magnetic resonance im-
aging (fMRI) evidence for reduced fronto-striatal and
temporo-parietal activation during visuo-spatial (Silk
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et al. 2005; Vance et al. 2007) and verbal WM tasks
(Kobel et al. 2009).
The stimulant methylphenidate (MPH) and the non-
stimulant atomoxetine (ATX) are the most commonly
prescribed pharmacological treatments for ADHD,
showing comparable efﬁcacy in 65–70% of cases
(Hazell et al. 2010). However, the drug-speciﬁc mech-
anisms of action on brain function in ADHD patients
are unknown.
MPH blocks dopamine (DA) transporters in the
striatum (Volkow et al. 1998) and norepinephrine
(NE) transporters (NET) in NET-rich regions including
prefrontal regions, where it enhances both catechol-
amines (Hannestad et al. 2010). ATX is a selective
pre-synaptic NET blocker affecting NE and DA in the
prefrontal cortex (Bymaster et al. 2002) and NE in the
thalamus, locus coeruleus and cerebellum, with mini-
mal striatal effects (Gallezot et al. 2011).
Placebo-controlled studies in medication-naive
ADHDpatients showed that a single dose ofMPHupre-
gulated and/or normalized the fronto-striatal, temporo-
parietal and cerebellar underactivations during cog-
nitive control tasks (Rubia et al. 2009a,b, 2011a,b), with
similar effects being reported in previously medicated
children compared with off-medication status (Vaidya
et al. 1998; Shafritz et al. 2004; Epstein et al. 2007).
Few fMRI studies, however, have tested for MPH
effects on WM in ADHD children, with inconsistent
results. Thus, in previously medicated ADHD children
compared with controls, MPH normalized the inferior
and medial frontal cortices (IFC/MFC) and striatal
underactivation during a delayed matched to sample
task (Prehn-Kristensen et al. 2011) and upregulated
activation and functional integration in fronto-parietal
WM networks during a Sternberg WM task (Wong &
Stevens, 2012). However, a single dose of MPH down-
regulated MFC and parietal activation during a
delayed WM match-to-sample task in female ADHD
subjects (Sheridan et al. 2010) or had no effects in
ADHD boys (Kobel et al. 2009). These studies, how-
ever, did not include a placebo condition, had small
sample sizes and recruited patients with a previous
history of stimulant medication, shown to affect both
brain activation and structure (Nakao et al. 2011;
Hart et al. 2012, 2013).
In the only placebo-controlled cross-over study com-
paring the effects of single-dose challenges of MPH
and ATX in medication-naive children with ADHD,
MPH showed drug-speciﬁc upregulation and normali-
zation effects during motor response inhibition in the
right IFC and cerebellum, while both drugs normal-
ized left IFC underactivation (Cubillo et al. 2012b).
However, no fMRI study has as yet investigated the
effects of ATX on brain activation in ADHD patients
during WM, or compared its effects with those of
MPH. In healthy adults, acute ATX administration
upregulates the IFC and superior temporal gyrus
(STG) activation during inhibitory tasks (Chamberlain
et al. 2009; Graf et al. 2011), and using multivariate
pattern recognition analyses ATX had relatively stron-
ger deactivation effects on the default-mode network
(DMN)while MPH has relatively stronger upregulating
effects on WM networks (Marquand et al. 2011).
We therefore conducted a randomized, double-
blind, placebo-controlled, cross-over pharmacological
fMRI study to test for drug-speciﬁc effects of a single
clinical dose of either MPH or ATX on brain activation
of medication-naive boys with ADHD during a WM
task. We chose a parametric verbal WM task, given:
(a) the impact of verbal WM deﬁcits on academic per-
formance; (b) prior evidence for impairments in this
task in ADHD children (Martinussen et al. 2005;
Willcutt et al. 2005; Pasini et al. 2007; Kobel et al.
2009); and (c) evidence for more pronounced impair-
ments in ADHD with increasing WM load (Goldberg
et al. 2005; Kobel et al. 2009; Gau & Shang, 2010). The
focus on single rather than long-term drug effects
on neurofunctional mechanisms avoids potential
confounds including side effects, symptomatic im-
provement or chronic effects on brain activation. We
furthermore compared brain activation during the
WM task in patients under each drug condition with
that of age-matched healthy controls to test for poten-
tial drug normalization effects. Based on previous evi-
dence on the n-back task, we hypothesized that ADHD
patients would be more impaired with increasing WM
load (Kobel et al. 2009). Based on previous fMRI
studies of WM in ADHD children (Prehn-Kristensen
et al. 2011), we hypothesized that ADHD boys would
show underactivation relative to controls in dorsolat-
eral prefrontal cortex (DLPFC) and parietal regions.
Furthermore, based on previous ﬁndings of fronto-
striatal upregulation by single doses of MPH of brain
activation in ADHD (Vaidya et al. 1998; Shafritz et al.
2004; Rubia et al. 2009a, 2011a,b; Prehn-Kristensen
et al. 2011) and of ATX on frontal brain activation in
healthy adults (Chamberlain et al. 2009; Graf et al.
2011), we hypothesized that both drugs would upregu-
late and normalize the reduced activation in the lateral
PFC and that MPH would additionally enhance basal
ganglia activation.
Method
Subjects
A total of 20 medication-naive right-handed boys
(aged 10–17 years) were recruited from clinics who
had a clinical diagnosis of ADHD, inattentive/hyper-
active-impulsive combined subtype, as assessed by
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an experienced child psychiatrist using the stan-
dardized Maudsley diagnostic interview that assesses
ADHD according to Diagnostic and Statistical
Manual of Mental Disorders, 4th edition, Text
Revision (DSM-IV-TR) criteria and is of standard use
in the UK (Goldberg & Murray, 2002). ADHD boys
scored above the clinical threshold for hyperactive-
impulsive/inattentive symptoms on the Strengths
and Difﬁculties Questionnaire for parents (SDQ;
Goodman & Scott, 1999), the Conners’ Parent Rating
Scale (CPRS-R; Conners et al. 1998), and below the
clinical threshold on the Social Communication Ques-
tionnaire (SCQ; Rutter et al. 2003) (Supplementary
Table 1). Patients were scanned in a double-blind,
placebo-controlled, cross-over design. On each scan-
ning session, they received a single dose of either pla-
cebo (vitamin C: 50mg), MPH (Equasym: 0.3mg/kg,
range 5−20mg) or ATX (Strattera: 1mg/kg, range
16–66mg), in a pseudo-randomized order, and re-
mained medication-free between scans. A Latin square
design was used for the randomization to achieve
counterbalanced effects. Dosages were determined fol-
lowing NICE guidelines of clinical efﬁcacious dosages
with minimal side effects at the time of the study
(National Institute for Heath and Clinical Excellence,
2008). Based on pharmacokinetic evidence, both medi-
cations were administered 1.5 h before the scan to
allow for maximum absorption (Chan et al. 1983;
Witcher et al. 2003). The same or similar dosages and
time lapses between drug administration and scan
have shown to be sufﬁcient to observe changes in
brain activation and performance in ADHD patients
(MPH) (Lijfﬁjt et al. 2006; Rubia et al. 2011a,b) and
healthy controls (ATX) (Chamberlain et al. 2007,
2009). All three medications were over-encapsulated
using the same capsules by the pharmacist.
A total of 20 right-handed healthy boys (aged 10–17
years) were recruited through advertisement in the
same geographical South London area of the UK.
They scored below clinical cut-offs for the SDQ, SCQ
and CPRS-R. They were scanned once, unmedicated.
Exclusion criteria for all participants were an intelli-
gence quotient (IQ) below 70 on the Wechsler
Intelligence Scale for Children, 4th version (WISC-IV;
Wechsler, 2004) (administered in the clinics: n=7) or
in the Wechsler Abbreviated Scale of Intelligence
(Wechsler, 1999) (administered in our laboratory:
n=13), history of substance abuse or neurological deﬁc-
its, presence of psychiatric disorders (except for ADHD
and conduct disorder/oppositional deﬁant disorder in
the ADHD group: n=2), learning disability, and read-
ing, speech or language disorder.
One-way analyses of variance (ANOVAs) showed
no between-group differences for age (F1,38 =0.88,
p<0.35) but did so for IQ (F1,38=42, p<0.001)
(Supplementary Table 1). Low IQ is associated with
ADHD (Bridgett & Walker, 2006). Although com-
monly conducted in case-control studies, analysis of
covariance is statistically illegitimate when the covari-
ate is an attribute of the disorder and when groups
were not randomly selected (Evans & Anastasio,
1968; Miller & Chapman, 2001; Dennis et al. 2009).
Furthermore, WM has been shown to be closely associ-
ated with IQ and is part of the WISC-IV (Wechsler,
2004). Therefore, co-varying for IQ during this task
would in fact mean co-varying for any potential
group differences in WM. Consequently, all analyses
were conducted without IQ as a covariate. However,
in order to test for potential effects of outliers, we
repeated the fMRI analyses excluding subjects with
an IQ more than 2 s.D. above or below average
(i.e. four subjects in each group).
Participants were paid £50 for each scanning session.
Parental/child informed consent/assent and approval
from the local ethical committee were obtained.
WM task (n-back)
Subjects practised the task once before scanning. The
6-min block design WM task (Ginestet & Simmons,
2011) consists of four conditions. During ‘1-back’,
‘2-back’ and ‘3-back’ conditions, subjects are presented
with series of letters (A–Z) (1 s duration, inter-trial
interval=2 s) and must respond with their right
thumb using a button box whenever the letter pre-
sented is the same as one, two or three before it,
respectively (e.g. 2-back: B/J/A/J). This requires both
storage and continuous updating of stimuli being
held in WM. In the baseline vigilance ‘0-back’ con-
dition, subjects must respond to each X that appears
on the screen. The task consists of 12 randomized
blocks. Before each block, written instructions of
3 s duration are shown as to which condition is next
(i.e. ‘0-back’, 1-back’, etc.). In each of the WM blocks
of 30 s duration only one WM condition is presented
(i.e. 2-back), and contains 15 stimuli: three targets
and 12 non-targets. Each condition is presented three
times. Performance data were recorded during scan-
ning. The dependent variable is accuracy (percentage
of correctly identiﬁed targets).
fMRI acquisition and analyses
Gradient-echo echoplanar MR imaging (EPI) data were
acquired on a GE Signa 3 T Horizon HDx system (Gen-
eral Electric, USA) at the Centre for Neuroimaging
Sciences, Institute of Psychiatry, King’s College
London, UK. A semi-automated quality-control pro-
cedure ensured consistent image quality (Simmons
et al. 1999). A quadrature birdcage head coil was
used for radio frequency transmission and reception.
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In each of 39 non-contiguous planes parallel to the
anterior–posterior commissure line, 186 T2*-weighted
MR images depicting blood oxygen level-dependent
(BOLD) contrasts covering the whole brain were
acquired (echo time=30ms, repetition time=2 s, ﬂip
angle=75°, in-plane resolution=3mm, slice thickness
=3.5 mm, slice-skip=0.5 mm). This EPI dataset pro-
vided complete brain coverage.
Blocked fMRI data were acquired in randomized
block presentation, and analysed using the non-
parametric XBAM software (Brammer et al. 1997;
Bullmore et al. 1999, 2001; Brain Image Analysis Unit,
2011). Methods for individual fMRI analyses and
group mapping are described in the Supplementary
text. For between-group comparisons, a 2×3 split plot-
design ANOVA (groups: controls, patients; WM load:
1-back, 2-back, 3-back, each separately contrasted
with 0-back) was conducted. For within-group com-
parisons, a 3×3 factorial-design repeated-measures
ANOVA (drug condition: placebo, MPH, ATX; WM
load: 1-back, 2-back, 3-back, separately contrasted
with 0-back) was conducted. Statistical measures of
BOLD response were extracted for each participant in
each of the clusters of activation differences for each
of the three contrasts, and post hoc analyses were con-
ducted to clarify the direction of the differences.
Within patients, repeated-measures ANOVAs on the
extracted BOLD response measures were conducted
to test for potential order effects.
Performance analysis
For the main performance measure of accuracy within
patients, repeated-measures ANOVAs were conducted
with drug condition (placebo, MPH, ATX) and WM
load (0-back, 1-back, 2-back, 3-back) as within-subject
factors. For case-control comparisons, three repeated-
measures ANOVAs (controls versus ADHD under
placebo; controls versus ADHD under MPH and con-
trols versus ADHD under ATX) were conducted with
WM load as the within-subjects factor and group
as the between-subjects factor. Repeated-measures
ANOVAs were used to test for potential scan order
effects.
Results
Performance data
Across all participants, there was a signiﬁcant WM
load effect in accuracy (F3,114=49, p<0.001), showing
that accuracy decreased with increasing WM load
(Table 1).
In case-control comparisons, no group effects were
found. However, as hypothesized, there was a signiﬁ-
cant interaction effect between WM load and group
in accuracy when healthy controls were compared
with patients under placebo (F3,114 =3, p<0.035) due
to patients being more accurate during 0-back and
1-back but less accurate during 2- and 3-back than
healthy controls (Table 1).
Within patients, no effects of drug condition or WM
load×drug condition were detected on performance
variables.
No other group, group×WM load interaction or
drug order effects were observed.
Brain activation
Motion
Participants were excluded if they had >3mm in the X
or Y dimensions. Multivariate ANOVA showed no sig-
niﬁcant group differences between controls and
ADHD patients under each drug condition in the
extent of mean rotation and translation movement par-
ameters in the three-dimensional Euclidean space
(F6,152=1, p=0.43).
Within-group brain activations
Within-group brain activations are shown in Supple-
mentary Fig. 1 and described in the Supplementary
text and Supplementary Table 2.
ANOVA between-group comparisons between
healthy controls and ADHD boys under placebo,
MPH or ATX
Placebo
Controls compared with patients under placebo
showed enhanced activation in the bilateral DLPFC
Table 1. Performance data for 20 healthy control boys and 20 boys with ADHD under each medication condition
Performance variable Task condition Controls ADHD placebo ADHD MPH ADHD ATX
Accuracy (% correct responses) 0-back 96 (11) 98 (4) 99 (3) 97 (8)
1-back 92 (17) 97 (6) 98 (6) 95 (16)
2-back 87 (22) 77 (26) 82 (25) 81 (26)
3-back 68 (21) 60 (28) 66 (24) 63 (27)
ADHD, Attention deﬁcit hyperactivity disorder; MPH, methylphenidate; ATX, atomoxetine.
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(Table 2, Fig. 1a). There was no enhanced activation in
patients compared with healthy controls.
Given that patients were less accurate than controls
in the 2- and 3-back conditions, we hypothesized that
accuracy would be positively correlated with DLPFC
activation in these conditions. Hence, one-tailed
Pearson correlations were conducted in both groups
separately between statistical measures of the BOLD
response in the left and right DLPFC and a composite
score of their accuracy during 2- and 3-back. At a trend
level, activation in the right DLPFC was correlated
positively with accuracy within controls (r=0.35, p<
0.06). No correlations were observed for left DLPFC
activation.
MPH
After the single dose of MPH, patients compared with
controls showed underactivation in the same left and
right DLPFC clusters as under placebo. However,
ADHD patients relative to controls showed additional,
enhanced activation in a cluster comprising the right
STG/premotor cortex, striatum/thalamus, insula, reach-
ing into the cerebellar vermis (Table 2, Fig. 1a). To test
whether the increased right medial fronto-STG-striatal
activation in patients under MPH was compensatory
for the reduced bilateral DLPFC activation, statistical
measures of BOLD response were extracted for each
patient in these three clusters and correlated with
the DLPFC activation clusters as well as with the ac-
curacy composite score. Pearson correlations showed
that the medial fronto-STG-striatal activation was
negatively correlated with the left DLPFC activation
(r=−0.5, p<0.012) and positively with accuracy (r=
0.37, p<0.05).
ATX
Under the single dose of ATX, patients compared with
controls still showed reduced activation in the left
DLPFC. However, they no longer showed underactiva-
tion of the right DLPFC. In addition, abnormally
enhanced activation was observed in ADHD relative
to controls in a right-lateralized cluster of IFC and
STG, insula, thalamus and striatum (Table 2, Fig. 1a),
which within patients was positively correlated with
accuracy (r=0.54, p<0.007).
Repeated-measures ANOVA within patients, for all
three contrasts, showed no signiﬁcant scan order
effects on the extracted BOLD response measures.
When those subjects whose IQ scores were more
than 2 s.D. above or below average were excluded,
all ﬁndings remained, although at a more lenient
p value (p<0.03).
Effect size comparisons of case-control conditions to
test for signiﬁcant ‘normalization’ effects
To establish whether the group differences between
controls and patients under each drug condition were
signiﬁcantly different, we directly compared the effect
sizes (ES) of the group differences from the three case-
control comparisons (Matthews & Altman, 1996) (see
details in the Supplementary text).
In the right DLPFC, the ES of the case-control con-
trast under ATX was signiﬁcantly different from the
ES of the case-control comparison under MPH (p<
0.03), suggesting that ATX signiﬁcantly enhanced acti-
vation in this region relative to MPH. For the cluster of
enhanced right fronto-STG-striatum activation under
MPH relative to controls the ES of the case-control con-
trast under MPH was signiﬁcantly higher than the ES
of the case-control comparisons under placebo (p<
0.004) and ATX (p<0.05). Finally, for the cluster of
enhanced right IFC-STG-striato-thalamic activation
under ATX relative to controls, the ES was signiﬁcantly
larger for the case-control contrast under ATX relative
to those of the case-control comparisons under placebo
(p<0.007) and under MPH (p<0.03) (Supplementary
Table 3).
ANOVA within-patient comparison between placebo,
MPH and ATX
Given the reduced activation in the left and right
DLPFC, we tested for signiﬁcant upregulation effects
of both drugs in the frontal cortex. The Talairach
Client (Lancaster et al. 1997, 2000) was used to deﬁne
a mask of the frontal lobe, restricting the analysis to
those voxels present in the mask. A signiﬁcant effect
of drug condition was observed in a cluster in the
right DLPFC [13 voxels, peak Talairach coordinates
(x, y, z): 25, 44, 26; Brodmann area (BA) 10/9, p<
0.044], which was due to signiﬁcantly enhanced acti-
vation when under ATX relative to MPH (p<0.002),
as well as when under placebo relative to MPH (p<
0.01) (Fig. 1b). There were no signiﬁcant correlations
between brain activation changes and performance.
Interaction effects
Between-groups comparisons: WM load×group
No signiﬁcant interaction effects were observed in the
comparison between healthy controls and patients
under placebo.
In the comparison between healthy and ADHD boys
under MPH, a signiﬁcant interaction of group×WM
load was observed in the left IFC reaching into the
DLPFC, putamen and anterior insula, due to enhanced
activation in ADHD under MPH relative to controls
during 2-back (p<0.01). Additional interaction effects
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Fig. 1. Results from the main group comparisons and the within-patient drug condition analysis. (a) Between-group analysis
of variance (ANOVA) comparisons between healthy control boys and boys with attention deﬁcit hyperactivity disorder
(ADHD) under either placebo (PLAC), methylphenidate (MPH) or atomoxetine (ATX) (main effect of group differences): axial
sections showing the ANOVA between-group differences in brain activation between healthy control boys and boys with
ADHD under each drug condition (placebo, MPH, ATX). For ease of view, clusters and their correspondent bar chart are
numbered. Clusters in orange denote areas where control boys showed enhanced activation compared with ADHD boys,
clusters in blue denote areas where ADHD boys showed enhanced activation compared with control boys. The graphs show
the statistical measure of blood oxygen level-dependent (BOLD) (brain activation) response in each area for each group and
working memory (WM) condition. The x-axis of the graphs corresponds to the statistical measure of the BOLD response in
this region. In the bar charts, the labels 1B, 2B and 3B denote the BOLD response of each group in the contrasts 1-back v.
0-back, 2-back v. 0-back and 3-back v. 0-back, respectively. (b) Within-patients ANOVA comparison (main effect of drug
condition). Axial sections showing the repeated-measures ANOVA results of drug condition within ADHD boys. The graphs
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were observed in bilateral occipital regions extending
to the cuneus, due to the enhanced deactivation of
this cluster in patients under MPH compared with con-
trols during 2-back (p<0.001) (Fig. 2a, Table 3).
In the comparison between controls and patients
under ATX, signiﬁcant interaction effects were
observed in the anterior and posterior cingulate
extending to the precuneus, due to signiﬁcantly
enhanced activation within patients relative to controls
during 1-back (p<0.004) and enhanced deactivation
during 3-back (p<0.005) (Fig 2a, Table 3).
Within-subjects comparison: WM load×drug condition
Signiﬁcant interaction effects were observed in the left
IFC [14 voxels, peak Talairach coordinates (x, y, z):
−36, 22, 9; BA 44/45, p<0.019 (p<0.04 Bonferroni
corrected)]) (Fig. 2b), due to signiﬁcantly enhanced
activation in this cluster during 2-back when under
MPH compared with placebo (p<0.001) and ATX
(p<0.015).
Repeated-measures ANOVAs showed no scan order
effect on the extracted BOLD response measures.
Discussion
The present fMRI comparison between single-dose
challenges of MPH and ATX on neural correlates of
WM in children with ADHD shows both shared as
well as drug-speciﬁc laterality effects on frontal acti-
vations. In line with previous studies, medication-
naive ADHD boys under placebo relative to controls
showed impaired performance under high but not
low WM load. This was accompanied by placebo-
associated underactivation in the left and right
DLPFC relative to controls. Both drugs had no effect
on within-subject performance, but normalized the
case-control performance deﬁcits in the more difﬁcult
2- and 3-back conditions in ADHD patients relative
to controls, which were no longer observed under
either drug. ATX had drug-speciﬁc modulation effects
on the right DLPFC, which was upregulated in ADHD
patients relative to MPH and signiﬁcantly normalized
in its underactivation relative to controls. By contrast,
MPH showed a drug-speciﬁc WM load-dependent
effect on the left-lateralized IFC,whichwas upregulated
during 2-back, both relative to controls (case-control
comparison), and relative to ATX and placebo (within-
subject contrast). Both drugs, in addition, elicited abnor-
mally enhanced activation inpatients relative to controls
in different fronto-STG-striatal networks, which were
associated with improved performance, suggesting
compensatory effects. The ﬁndings therefore show
both drug-speciﬁc laterality effects in the upregulation
of prefrontal WM regions as well as shared effects of
recruiting compensatory brain areas.
ADHD patients under placebo relative to controls
showed no deﬁcits during the ﬁrst easy WM task con-
dition. However, they were less accurate than controls
during the 2-back and 3-back conditions, in line with
prior evidence for more pronounced deﬁcits in
ADHD patients with increased task difﬁculty during
verbal n-back (Kobel et al. 2009) and visuo-spatial
WM tasks (Goldberg et al. 2005; Gau & Shang, 2010).
Although neither drug improved performance within
patients, the case-control analyses showed that both
drugs normalized the between-group accuracy deﬁcits
in the 2- and 3-back condition, as they were no longer
observed. The ﬁndings are in line with evidence that
MPH normalizes the performance deﬁcits shown by
ADHD patients relative to controls in a verbal n-back
(Kobel et al. 2009). The normalization effects suggest
relatively small accuracy improvements that were
probably underpowered to emerge in the within-
subject analyses.
Compared with controls, patients showed underacti-
vation in the bilateral DLPFC, a key region for WM,
involved in the storage and coding of the temporal
sequence of stimuli (Owen et al. 2005). The ﬁndings
extend previous evidence of underfunctioning of the
DLPFC in adult ADHD during WM (Valera et al.
2010) and in ADHD children during other attention
and executive function tasks (Rubia, 2011; Cubillo
et al. 2012a, Hart et al. 2012; Christakou et al. 2013).
The most interesting ﬁndings are those of drug-
speciﬁc lateralization effects on frontal activations.
While ATX showed a drug-speciﬁc right-hemispheric
DLPFC upregulation and normalization effect relative
to MPH, MPH showed a drug-speciﬁc left-lateralized
WM load-dependent upregulation effect on left IFC/
DLPFC activation during the 2-back condition
relative to ATX within patients and relative to controls.
show the statistical measure of BOLD response in the cluster for drug condition and WM load condition. The x-axis of the
graphs corresponds to the statistical measure of the BOLD response in this region. In the bar charts, the labels 1B, 2B and 3B
denote the BOLD response of each group in the contrasts 1-back v. 0-back, 2-back v. 0-back and 3-back v. 0-back, respectively.
Talairach z-coordinates are indicated for slice distance (in mm) from the intercommissural line. The right side of the image
corresponds to the right side of the brain. The maps are thresholded to give less than one type I error three-dimensional
cluster per map (p<0.01). L, Left; DLPFC, dorsolateral prefrontal cortex; R, right; STG, superior temporal gyrus; IFC, inferior
frontal cortex.
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Fig. 2. Interaction effects with working memory (WM) load. (a) Axial sections showing the interaction effects between WM
load and group for the between-group comparisons between healthy controls and boys with attention deﬁcit hyperactivity
disorder (ADHD) under methylphenidate (MPH), and between healthy controls and ADHD boys under atomoxetine (ATX).
The graphs show the blood oxygen level-dependent (BOLD) response in each area for each group and WM load condition. In
the bar charts, the labels 1B, 2B and 3B denote the BOLD response of each group in the contrasts 1-back v. 0-back, 2-back v.
0-back and 3-back v. 0-back, respectively. Clusters in orange denote areas where control boys showed enhanced activation
compared with ADHD boys, clusters in blue denote areas where ADHD boys showed enhanced activation compared with
control boys. (b) Axial section showing the interaction effects of WM load and drug condition for the within-ADHD ANOVA.
The graph shows the BOLD response in each area for each drug condition during each WM load condition. In the bar charts,
the labels 1B, 2B and 3B denote the BOLD response of each group in the contrasts 1-back v. 0-back, 2-back v. 0-back and
3-back v. 0-back, respectively. Talairach z-coordinates are indicated for slice distance (in mm) from the intercommissural line.
The right side of the image corresponds to the right side of the brain. The maps are thresholded to give less than one type I
error three-dimensional cluster per map (p<0.01). L, Left; IFC, inferior frontal cortex; Bilat, bilateral; ACC/PCC/Pcu, anterior
cingulate/posterior cingulate cortex/precuneus; PLAC, placebo.
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The ﬁndings suggest potential differences in their
effects on underlying catecholaminergic systems. WM
is mediated in the DLPFC by noradrenergic α2 recep-
tors that increase neural ‘signalling’ (increased ﬁring
to relevant stimuli) and by dopaminergic D1 receptors
that decrease ‘noise’ (suppressing ﬁring to irrelevant
stimuli) (Gamo et al. 2010). Although ATX affects
both DA and NE in the PFC (Bymaster et al. 2002), in
non-human primates it increases ‘signalling’ more fre-
quently than it decreases ‘noise’ (Gamo et al. 2010).
This study thus shows for the ﬁrst time that upregu-
lation of right frontolateral activation is not only
observed with a single dose of ATX in healthy adults
(Chamberlain et al. 2009; Graf et al. 2011), but also in
children with ADHD, implying similar mechanisms
of action in both healthy subjects and ADHD patients.
Most importantly, however, we show that, during
WM, the right frontal normalization and upregulation
effects with ATX are drug-speciﬁc relative to MPH.
Interestingly, the ﬁnding of left IFC upregulation
under the 2-back with MPH reﬂects the association
between dopaminergic striatal function and left IFC
activation during WM maintenance (Landau et al.
2009), in line with previous ﬁndings of predominantly
left-hemispheric upregulation and normalization
effects (Epstein et al. 2007; Rubia et al. 2009a, 2011b).
Table 2. Group differences in brain activation for between-group ANOVA comparisons between controls and boys with ADHD under either
the placebo, MPH or ATX conditiona
Subject contrast Brain regions of activation
Brodmann
area
Peak Talairach
coordinates:
x, y, z
Voxel
number
Cluster
p value
(corrected) Cohen’s d
Control>ADHD
placebo
Right medial/superior frontal 9/8 25, 37, 31 129 0.01 (0.02) 1.28
Left medial/superior/inferior frontal 9/8 –25, 44, 31 129 0.008 (0.016) 1.51
Control>ADHD
MPH
Right medial/superior frontal 9/8 25, 44, 31 201 0.001 (0.002) 1.90
Left medial/superior frontal 9/8 –25, 44, 31 143 0.002 (0.004) 1.73
ADHD
MPH>control
Right superior temporal/
parahippocampal gyri/premotor
cortex/basal ganglia/thalamus/insula/
amygdala/vermis cerebellum
36/22/6 18, –15, –24 297 0.005 (0.01) 1.60
Control>ADHD
ATX
Left medial/superior frontal 9/8 –25, 41, 37 169 0.004 (0.008) 1.65
ADHD
ATX>control
Right inferior frontal/insula/medial/
superior temporal/amygdala/basal
ganglia/thalamus
44/45/21/22 29, –15, –7 395 0.003 (0.006) 1.82
ANOVA, Analysis of variance; ADHD, attention deﬁcit hyperactivity disorder; MPH, methylphenidate; ATX, atomoxetine.
a The maps are thresholded to give less than one type I error three-dimensional cluster per map.
Table 3. Group×WM load interaction effects on brain activation for between-group ANOVA comparisons between controls and boys with
ADHD under either the placebo, methylphenidate or atomoxetine conditiona
Subject contrast
Brain regions
of activation
Brodmann
area
Peak Talairach
coordinates:
x, y, z
Voxel
number
Cluster
p value
(corrected) Cohen’s d
ADHD MPH>
control
Left inferior/middle/
superior frontal/putamen
44/45/10/46/9 –36, 22, 4 237 0.007 (0.014) 0.85
Control>ADHD
MPH
Right and left medial
occipital/cuneus/middle
temporal gyri
17/18/19/39 –25, –85, 20 546 0.001 (0.002) 1.18
Control>ADHD
ATX
Right anterior/posterior
cingulate gyri/precuneus
24/32/23/31/7 11, 15, 26 167 0.004 (0.008) 0.98
WM, Working memory; ANOVA, analysis of variance; ADHD, attention deﬁcit hyperactivity disorder; MPH,
methylphenidate; ATX, atomoxetine.
a The maps are thresholded to give less than one type I error three-dimensional cluster per map.
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Therefore, the ﬁndings could possibly suggest stronger
effects of ATX on predominantly right-lateralized
NE-mediated WM and attention networks (Tucker &
Williamson, 1984), while MPH showed stronger effects
on predominantly left-lateralized fronto-striatal DA
systems (Glick et al. 1982; Flor-Henry, 1986).
The enhanced deactivation with both drugs in
regions of the DMN in ADHD relative to controls
during the high WM load conditions suggest that
catecholamine reuptake inhibitors not only increase
task-positive but also switch off task-negative DMN
activation. The ﬁndings extend prior evidence of en-
hanced DMN deactivation with MPH during motor
inhibition in previously medicated patients relative
to an off-medication condition (Liddle et al. 2010) to
medication-naive patients in a placebo-controlled
design for another task and furthermore show for the
ﬁrst time that this effect is shared by ATX.
Both drugs showed abnormally enhanced fronto-
STG-striatal activation in ADHD boys relative to
controls, although in somewhat different locations, af-
fecting the premotor cortex with MPH and the right
IFC with ATX. The ﬁndings echo previous ﬁndings
of fronto-temporo-striatal upregulation/normalization
in ADHD children with MPH during WM (Prehn-
Kristensen et al. 2011) and other cognitive control
tasks (Vaidya et al. 1998; Epstein et al. 2007; Rubia
et al. 2011a,b) and extend for the ﬁrst time previous evi-
dence of enhanced IFC/STG activation after a single-
dose ATX challenge in healthy adults (Chamberlain
et al. 2009) to a paediatric ADHD group.
The strength of the study is the double-blind,
placebo-controlled design and the recruitment of
medication-naive children with ADHD, which avoids
the confound of a previous history of stimulant medi-
cation (Nakao et al. 2011; Hart et al. 2012).
A limitation is the fact that groups differed in IQ.
However, the ﬁndings survived when outliers were
excluded from the analyses.
An important caveat is that while MPH has an im-
mediate effect on ADHD symptoms (Greenhill et al.
2001), ATX reaches its maximum clinical efﬁcacy
after 12 weeks of treatment (Montoya et al. 2009).
Given the differences of the two drugs in temporal
courses to clinical efﬁcacy, however, future studies
should also compare their long-term effects on brain
activation when they have reached maximum clinical
efﬁcacy. Also, while a within-group design was crucial
to assess differential drug effects, it has the disadvan-
tage that only one group was medication-naive in the
second drug and none in the third drug condition.
However, the 7 days’ break between scans should
have minimized carry-over effects. MPH has a 3.9 h
half-life (Modi et al. 2000). For ATX, the plasma half-life
is 3 h for fast metabolizers and 16–25 h for poor
metabolizers (single dose and steady state) (Sauer
et al. 2003; Witcher et al. 2003) and hence effects should
have been washed out after 1 week. While we used the
smallest clinical dosages with minimal side effects at
the time of the study as recommended by the NICE
guidelines (National Institute for Heath and Clinical
Excellence, 2008), some children with ADHD receive
higher dosages in clinical practice, which could lead
to more pronounced effects and long-term changes in
catecholaminergic systems. A further limitation is
that ADHD boys performed the task three times,
while, for ﬁnancial and ethical reasons, controls were
scanned only once, unmedicated. However, the coun-
terbalanced randomized design for the ADHD group
adequately controlled for practice effects in patients,
and we found no order effects for the within or the
case-control studies, which suggests that these were
unlikely to have confounded the between-groups ana-
lyses. Also, we included a relatively large age range.
While this does not affect the within-subject analyses
and controls were age-matched, a smaller age range
may have resulted in less variance and more reﬁned
changes particular to speciﬁc ages, given developmen-
tal changes between late childhood and adolescence
during WM and other executive functions (Crone
et al. 2006; Bunge & Wright, 2007; Rubia, 2012).
Furthermore, due to the higher prevalence of ADHD
in boys (Merikangas et al. 2010), we only tested male
adolescents, which limits the generalizability of the
ﬁndings.
In conclusion, the ﬁndings show both drug-speciﬁc
as well as shared effects on task-positive and task-
negative WM networks. ATX appears to have a drug-
speciﬁc effect of upregulating and normalizing
WM-related right DLPFC dysfunction in ADHD,
while MPH appears to upregulate compensatory acti-
vation of left IFC activation, but only during the
2-back condition.
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